The global TB drug market was valued at USD 886 million in 2016 and is expected to surpass USD 1,036 million by 2021, says Technavio.
Technavio has announced its latest market research report on the global TB drug market, under its infectious and rare diseases portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like Lupin, Otsuka Novel Products, Pfizer, Sandoz, and Sanofi.
According to Barath Palada, a lead analyst for infectious and rare diseases research at Technavio, “The emergence of MDR-TB and XDR-TB strains will have a positive impact on the global tuberculosis drugs market. The emergence of drug-resistant strains of TB is on the rise in India and China, which account for more than half of the global MDR-TB burden.”
As per the research studies, MDR-TB rates are the highest in Eastern Europe, where MDR-TB accounts for around 16-22% of all new TB cases. According to CDC (Centers for Disease Control and Prevention), it is estimated that XDR-TB is present in all regions of the world, but it is most prevalent in countries of the former Soviet Union and Asia. India is contributing nearly one-third of the world’s TB cases, and the prevalence of MDR-TB is on the rise in India.
Click here to request a free sample of this report
Increased spending on TB diagnostic kits
Annually, over USD 1 billion is spent worldwide on TB diagnosis, which is almost twice the amount spent on TB drugs. In order to tap the growing commercial potential of TB-HIV co-infection outbreak, companies are putting their efforts into emerging economies, particularly India and China, to develop affordable diagnostics against TB and HIV.
Increased focus on TB vaccine development
Currently, the BCG vaccine is the only vaccine available for TB. The vaccine is given to children to protect against the disseminated forms of TB in children, including TB meningitis. On the other hand, WHO is no longer recommending BCG vaccine for the treatment of TB in HIV-infected infants. To fight this, a strong pipeline of new vaccines has emerged over the years into the clinical trials. Vendors are focusing more on developing effective vaccines against the spread of the TB infection.
Ask an analyst to know more about this report
This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio market research report titled, ‘Global TB Drug Market 2017-2021‘. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Atopic Dermatitis Drugs Market 2017-2021
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
To read more press releases – click here
